- Business Wire•4 hours agoNew Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients
Bristol-Myers Squibb Company today announced new results from CheckMate -205, a multi-cohort, single-arm, Phase 2 trial evaluating Opdivo in patients with classical Hodgkin lymphoma .
Bristol-Myers Squibb Company (BMY) announced that its supplemental biologics license application (sBLA) for immuno-oncology drug Opdivo has been accepted for priority review by the FDA.
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||49.81 x 2000|
|Ask||49.82 x 300|
|Day's Range||49.03 - 50.13|
|52wk Range||49.03 - 77.12|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||29.14|
|Avg Vol (3m)||14,221,986|
|Dividend & Yield||1.52 (3.04%)|